OTCMKTS:ANTH Anthera Pharmaceuticals (ANTH) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisChartFinancialsSEC FilingsShort Interest Get Anthera Pharmaceuticals alerts: Email Address About Anthera Pharmaceuticals Stock (OTCMKTS:ANTH) 30 days 90 days 365 days Advanced Chart Ad Weiss RatingsFDA’s hidden signal greenlights biotech winners — 97% of the timeThe FDA has started to quietly send out a signal … That has given investors a 97% chance of making money. Perhaps as soon as 9:30 a.m. tomorrow. Click here to find out how you can get in before the FDA’s potential signal. Get ANTH alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket Capitalization$1,000.00P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAnthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.Read More… FDA’s hidden signal greenlights biotech winners — 97% of the time (Ad)The FDA has started to quietly send out a signal … That has given investors a 97% chance of making money. Perhaps as soon as 9:30 a.m. tomorrow. Click here to find out how you can get in before the FDA’s potential signal. Receive ANTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anthera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ANTH Stock News HeadlinesMACK - Merrimack Pharmaceuticals, Inc.June 28, 2023 | finance.yahoo.comIndustry Research Report on Cystic Fibrosis Drugs Market Share and Industrial Overview till 2030May 16, 2023 | marketwatch.comKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… September 29, 2024 | Paradigm Press (Ad)Systemic Lupus Erythematosus (SLE) Drugs Market Updates: 2023-2030 ForecastMay 16, 2023 | marketwatch.com2023-2030 Vasculitis Treatment Market Size (Growth and Outlook) includes Main Business Overview | with [124 Pages]May 5, 2023 | marketwatch.com2023-2030 Gaucher Disease Treatment Market Size (Growth and Outlook) includes Company Information | with [104 Pages]May 4, 2023 | marketwatch.comGaucher Disease Treatment Market Top Key Players by 2030April 28, 2023 | marketwatch.comGlobal Cystic Fibrosis Drugs Market Size 2023 to 2026 Size and Share Survey ReportApril 7, 2023 | marketwatch.comSee More Headlines ANTH Stock Analysis - Frequently Asked Questions How were Anthera Pharmaceuticals' earnings last quarter? Anthera Pharmaceuticals, Inc. (OTCMKTS:ANTH) announced its quarterly earnings data on Monday, March, 5th. The biopharmaceutical company reported ($0.73) EPS for the quarter, beating the consensus estimate of ($0.82) by $0.09. When did Anthera Pharmaceuticals' stock split? Anthera Pharmaceuticals's stock reverse split on Monday, May 1st 2017. The 1-8 reverse split was announced on Friday, April 28th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 28th 2017. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. How do I buy shares of Anthera Pharmaceuticals? Shares of ANTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Anthera Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Anthera Pharmaceuticals investors own include Ocular Therapeutix (OCUL), Novavax (NVAX), Synergy Pharmaceuticals (SGYP), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Arena Pharmaceuticals (ARNA) and OPKO Health (OPK). Company Calendar Last Earnings3/05/2018Today9/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:ANTH CUSIPN/A CIK1316175 Webwww.anthera.com Phone(410) 350-1839Fax510-856-5597Employees20Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares5,750,000Free FloatN/AMarket Cap$1,000.00 OptionableNot Optionable Beta1.91 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (OTCMKTS:ANTH) was last updated on 9/29/2024 by MarketBeat.com Staff From Our PartnersThe Bible Says it Clear As DayIt came to me clear-as-day thanks to the Bible… in the Parable of Talents, in the book of Matthew… This pa...Prosperity Research | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredThe most serious warning of my careerWith the 2024 election just weeks away, a new crisis is barrelling down on America… one that could cleave the ...Porter & Company | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredThe $15 "Insider Secret" That Could Save Your RetirementWhat if I told you there's a $15 stock that a billionaire insider just poured $47 MILLION into? That's righ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anthera Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anthera Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.